BCR ABL 1 Kinase Domain Mutation Analysis
This test detects mutations in the kinase domain of the BCR-ABL gene, which may indicate resistance to certain leukemia treatments. It helps guide therapy choices in chronic myelogenous leukemia (CML).
BCR ABL 1 Kinase Domain Mutation Analysis Test in Vadodara Overview
No special preparations needed
- Specimen
- Bcr-abl 1 Kinase Domain Mutations
This test detects mutations in the kinase domain of the BCR-ABL fusion gene, which can cause resistance to tyrosine kinase inhibitors (TKIs) used in treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
- Patients with CML or Philadelphia chromosome-positive ALL who are not responding to TKIs.
- Individuals experiencing disease relapse after TKI treatment.
- Monitoring for drug resistance in long-term therapy.
A blood or bone marrow sample is analyzed using PCR and sequencing methods to identify mutations in the BCR-ABL gene.
- Mutations detected: May suggest resistance to certain TKIs, requiring a change in treatment.
No mutations detected: The treatment may need to be adjusted due to other factors, not mutations.
Identifying mutations in BCR-ABL helps determine the most effective therapy and prevent disease progression.
Test code
5351
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Edta Whole Blood | Lavender Vacutainer | 3 ML |
Specimen stability information
Edta Whole Blood
Specimen rejection criteria
Test run frequency
Every Day TIME - 10:00
Turn around time
10 Working Days
Performing locations
Department
- Advanced Molecular Diagnostics R&d
CPT and Loinc codes
Package price
₹11000
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestBCR ABL 1 Kinase Domain Mutation Analysis
₹11000